Sex- and age-adjusted association between interleukin-6 levels at baseline and over the 5-year exposure period and aging phenotypes at 10-year follow-up *
| Variable |
Successful aging
†
n = 721 |
Fatal or nonfatal CVD event
n = 321 |
Non-CVD death
n = 147 | |||
|---|---|---|---|---|---|---|
| No. of patients | OR (95% CI) | No. of patients | OR (95% CI) | No. of patients | OR (95% CI) | |
| Interleukin-6 level ‡ at baseline | ||||||
| Low (ref) | 257 | 1.00 | 49 | 1.00 | 19 | 1.00 |
| Intermediate | 344 | 0.64 (0.53–0.78) | 158 | 1.47 (1.04–2.06) | 58 | 1.39 (0.81–2.36) |
| High | 120 | 0.36 (0.28–0.46) | 114 | 1.97 (1.37–2.82) | 70 | 3.06 (1.80–5.18) |
| No. of times interleukin-6 level was high over 5-yr exposure period § | ||||||
| 0 (ref) | 526 | 1.00 | 164 | 1.00 | 67 | 1.00 |
| 1 | 145 | 0.58 (0.47–0.72) | 98 | 1.47 (1.12–1.93) | 41 | 1.48 (0.99–2.21) |
| 2 | 50 | 0.42 (0.31–0.58) | 59 | 1.54 (1.30–2.35) | 39 | 2.75 (1.80–4.20) |
Note: CI = confidence interval, CVD = cardiovascular disease, OR = odds ratio, ref = reference group.
↵ * Age- and sex-adjusted logistic regression assessed associations of inflammation with 3 outcomes: successful aging (v. normal aging, CVD event and non-CVD death phenotypes combined), total n = 3044; fatal or nonfatal CVD event (v. successful and normal aging phenotypes combined), total n = 2897 (excludes 147 participants who had a non-CVD death); and non-CVD death (v. successful and normal aging phenotypes combined), total n = 2723 (excludes 321 participants who had CVD event).
↵ † Free of major chronic disease and with optimal physical, mental and cognitive functioning.
↵ ‡ Low = ≤ 1.0 ng/L, intermediate = 1.1–2.0 ng/L, high = > 2.0 ng/L.
↵ § Interleukin-6 was measured twice (5 yr before baseline and at baseline); 0 = neither measurement was high, 1 = either measurement was high, 2 = both measurements were high.